Irinotecan has 14 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Itraconazole, Ketoconazole, Sofosbuvir, Velpatasvir, And Voxilaprevir. Patients taking Irinotecan should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 14
- Contraindicated
- 2
- Major
- 1
- Moderate
- 5
- Minor
- 6
Contraindicated (2)
- Irinotecan + Itraconazole— Coadministration is contraindicated. Itraconazole increases plasma concentrations, potentially increasing pharmacologic …
- Irinotecan + Ketoconazole— Coadministration of ketoconazole with irinotecan is contraindicated.
Major (1)
- Irinotecan + Sofosbuvir, Velpatasvir, And Voxilaprevir— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
Moderate (5)
- Irinotecan + Eltrombopag— BCRP substrate (SN-38 metabolite); eltrombopag may increase exposure. Monitor closely for excessive drug exposure.
- Irinotecan + Eltrombopag Olamine— BCRP substrate (active metabolite SN-38); monitor for excessive exposure and consider dose reduction if appropriate.
- Irinotecan + Gemfibrozil— OATP1B1 substrate (active metabolite SN-38); gemfibrozil inhibition may increase irinotecan exposure, requiring dosing r…
- Irinotecan + Netupitant And Palonosetron— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Irinotecan + Rolapitant— Increased plasma concentrations may result in potential adverse reactions. Monitor for adverse reactions if use cannot b…
Minor (6)
- Irinotecan + Bevacizumab— No clinically meaningful effect on pharmacokinetics of irinotecan when administered with bevacizumab.
- Irinotecan + Bevacizumab-Adcd— No clinically meaningful effect on pharmacokinetics of irinotecan or its active metabolite SN38 when administered with b…
- Irinotecan + Bevacizumab-Awwb— No clinically meaningful effect on irinotecan pharmacokinetics observed when administered with bevacizumab.
- Irinotecan + Bevacizumab-Bvzr— No clinically meaningful effect on irinotecan pharmacokinetics observed when bevacizumab was administered in combination…
- Irinotecan + Bevacizumab-Maly— No clinically meaningful effect on the pharmacokinetics of irinotecan observed when bevacizumab was administered in comb…
- Irinotecan + Bevacizumab-Nwgd— No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38 when bevacizumab was…